EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Extrapolating the speed of psoriasis clearance: Head-to-head agents in clinical trials

Creighton Pfau, Katie K Lovell, Hanna Ozbeki, Steven R Feldman

Dermatology Online Journal · 09.05.2026 · 32 (2)

DOI: 10.25251/t1b8ft53 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatology Online Journal, online erschienen am 09.05.2026. Verfasst von Creighton Pfau und 3 weiteren Autor:innen. Beteiligte Einrichtung: AT Still University School of Osteopathic Medicine in Arizona, Mesa, AZ, USA. Hauptthemen laut MEDLINE: Dermatologic Agents, Interleukin-17, Interleukin-23, Psoriasis. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Biologic therapies targeting interleukin-17 (IL-17) and interleukin-23 (IL-23) pathways have transformed psoriasis management, with IL-17 inhibitors widely regarded as achieving faster clearance. However, the clinical significance of differences in clearance times remains unclear.

Objective

To compare time to achieve a 75% reduction in the Psoriasis Area and Severity Index (PASI75) between IL-17 and IL-23 inhibitors using data from head-to-head clinical trials.

Methods

A PubMed search identified trials reporting PASI75 response times for IL-17 and IL-23 inhibitors. Graphs from 12 studies were analyzed using Engauge Digitizer Software to estimate the time until half of participants reached PASI75.

Results

IL-17 inhibitors achieved PASI75 faster than IL-23 inhibitors, with average response times of 4.5 weeks versus 7 weeks, respectively. The fastest IL-17 agent (bimekizumab) reached PASI75 in 2.5 weeks, while the fastest IL-23 agent (risankizumab) required 5.5 weeks. Differences between classes were smaller than anticipated, particularly for newer IL-23 inhibitors targeting the p19 subunit.

Limitations

PASI75 timepoints were estimated from published graphs, introducing potential measurement error.

Conclusion

IL-17 inhibitors generally achieve faster psoriasis clearance than IL-23 inhibitors, but the clinical relevance of this difference is limited. Safety and long-term efficacy profiles should guide treatment selection, highlighting the importance of personalized patient care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatologic AgentsInterleukin-17Interleukin-23PsoriasisHumansAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedClinical Trials as TopicSeverity of Illness IndexTime FactorsUstekinumab

Stichwörter der Autor:innen

PASIbiologicspsoriasisspeed of responsetrials

Substanzen

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedbimekizumabDermatologic AgentsInterleukin-17Interleukin-23risankizumabUstekinumab

Autor:innen und Institutionen

  • AT Still University School of Osteopathic Medicine in Arizona, Mesa, AZ, USA.
  • Department of Dermatology, Center for Dermatology Research, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
  • Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
  • Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
  • Department of Social Sciences & Health Policy, Wake Forest University School of Medicine, Winston-Salem, NC, USA.

Zitieren

APA

Pfau, C., Lovell, K. K., Ozbeki, H., & Feldman, S. R. (2026). Extrapolating the speed of psoriasis clearance: Head-to-head agents in clinical trials. Dermatology Online Journal, 32(2). https://doi.org/10.25251/t1b8ft53

Vancouver

Pfau C, Lovell KK, Ozbeki H, Feldman SR. Extrapolating the speed of psoriasis clearance: Head-to-head agents in clinical trials. Dermatology Online Journal. 2026;32(2). doi:10.25251/t1b8ft53

BibTeX
@article{Pfau2026,
  author = {Pfau, Creighton and Lovell, Katie K and Ozbeki, Hanna and Feldman, Steven R},
  title = {Extrapolating the speed of psoriasis clearance: Head-to-head agents in clinical trials},
  journal = {Dermatology Online Journal},
  year = {2026},
  volume = {32},
  number = {2},
  doi = {10.25251/t1b8ft53}
}
Kostenlos starten →